Several Overseas Crypto Whales Increase Their ETH Holdings, Ethereum Finally Sees Long-Awaited Rebound
BlockBeats News, March 16th. Today Ethereum saw a long-awaited rebound, with a nearly 8% daily increase, now trading at $2260.49. Behind this strong rebound, multiple overseas whales simultaneously took spot position increase actions.
Among them, represented by ShapeShift founder and early Bitcoin supporter Erik Voorhees, who purchased 21,293 ETH at an average price of $2091 in the past 6 days, worth approximately $44.52 million.
In addition, early Ethereum builder and crypto whale billΞ.eth increased his holdings by 7769 ETH in the past 3 hours.
In addition to well-known whales, anonymous new addresses have also been quietly accumulating. Including a new address at noon today withdrawing 20,000 ETH from an exchange, worth approximately $44.83 million.
Another whale, 0x743d, spent 3.79 million USDT on the 14th to purchase an additional 1827 ETH. Over the past 6 days, this whale has spent $24.79 million to purchase 11,985 ETH at an average price of $2068.
The whale address "0x083" sold 50 BTC (worth $3.52 million) on the 15th to buy 1693 ETH, now holding 5698 ETH (worth $11.92 million).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
